Filing Details

 

	SECURITIES AND EXCHANGE COMMISSION
	Washington, DC 20549
	SCHEDULE 13D

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

(Name of Issuer)

 

(Title of Class of Securities)

 

(CUSIP Number)

 

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

2

 

Item 1.                                 Security and Issuer.

 

This Amendment No. 2 to Schedule 13D is being filed as an amendment to the initial statement on Schedule 13D relating to the Common Stock, $0.001 par value per share (Common Stock) of Akcea Therapeutics, Inc., a Delaware corporation (the Issuer) as filed with the Securities and Exchange Commission (the SEC) on July 27, 2017 (the Original Schedule 13D) as amended by Amendment No. 1 filed April 26, 2018.  The principal executive offices of the Issuer are located at 55 Cambridge Parkway, Suite 100, Cambridge MA 02142.  This Amendment is being filed to report the acquisition of an aggregate of 1,597,571 shares of the Issuers Common Stock by Ionis Pharmaceuticals, Inc., a Delaware corporation (Ionis or the Reporting Person), on August 3, 2018.

 

Items 2(c), 4 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect.  All capitalized terms used in this Amendment No. 2 but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

 

Item 2.                                 Identity and Background.

 

Schedule A to Item 2(c) is hereby amended.

 

Item 4.                                 Purpose of Transaction.

 

Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 4:

 

On August 3, 2018, the Reporting Person received 1,597,571 shares of the Issuers Common Stock in satisfaction of the Issuers obligations to the Reporting Person pursuant to that certain License Agreement, dated March 14, 2018, between the Issuer and the Reporting Person.

 

Item 5.                                 Interest in Securities of the Issuer.

 

Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

 

The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Person filing this Schedule 13D is provided as of August 3, 2018:

 

(a)         The Reporting Person beneficially owns 65,712,116 shares of the Common Stock of the Issuer, or approximately 77% of the Issuers outstanding Common Stock.

 

(b)         Ionis has sole power to vote and dispose of the securities of the Issuer held by it.

 

(c)          The Reporting Person has not effected any other transactions in the Issuers Common Stock within the past sixty days, except as provided herein.

 

(d)         Not applicable.

 

(e)          Not applicable.

 

Item 6.                                 Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

None.

 

Item 7.                                 Material to be Filed as Exhibits.

 

None.

 

3

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Date: August 6, 2018	IONIS PHARMACEUTICALS, INC.
	By:	/s/ Elizabeth L. Hougen
		Elizabeth L. Hougen
		Chief Financial Officer

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representatives authority to sign on behalf of such person shall be filed with the statement:  provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

Attention:                                        Intentional misstatements or omissions of fact
constitute Federal criminal violations (See 18 U.S.C. 1001)

 

4

 

SCHEDULE A
DIRECTORS AND EXECUTIVE OFFICERS OF IONIS

 

The following table sets forth the name, business address, present principal occupation or employment and material occupations, positions, offices or employment of each of the directors and executive officers of Ionis.  All directors and executive officers listed below are citizens of the United States unless otherwise noted herein.

 

DIRECTORS

 

 

OFFICERS

 

 

5

 

 

6